COST CONTAINMENT VS QUALITY IN HEALTH CARE

6 December 1993

The health care industry is recession-proof and its costs steadily increase, despite the stagnation of other sectors of the economy, according to a new Financial Times Management report which examines the various cost-containment measures being adopted to constrain health care prices.

The report's authors, Eleanor Feldbaum and Miriam Hughesman, concentrate on the cost-containment efforts and quality of health services in the UK, France, Germany and the USA, since they believe their health systems represent a broad spectrum of methods of financing and regulating the provision of health care.

The UK stands at one end of the spectrum, with a health system supported primarily by general revenues, while the USA is at the other end, dominated by the private insurance sector. Between them lie France, where health costs are paid by worker contributions to social security, and Germany, where contributions are made to about 1,200 insurance funds. The provision of health care varies between the UK system, where the National Health Service pays for and manages health care services, and the USA, which relies on private, independent health care providers. France and germany have independent ambulatory services, and their in-patient or hospital services are dominated by the public sector.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight